Skip to main content
MedPathMedPath Home
Clinical Trials/PER-076-11
PER-076-11
Unknown
未知

A RANDOMIZED, DOUBLED-BLIND, DOUBLE-DUMMY, PLACEBO CONTROLLED MULTI-CENTRE STUDY TO EVALUATE THE EFFICACY AND SAFETY OF FLUTICASONE FUROATE INHALATION POWDER AND FLUTICASONE PROPIONATE INHAATION POWDER IN THE TREATMENT OF ASTHMA IN ADULTS AND ADOLESCENTS NOT CURRENTLY TREATED WITH INHALED CORTICOSTEROIDS

GLAXOSMITHKLINE PERU S.A.,0 sites119 target enrollmentNovember 23, 2011
Share to TwitterShare to FacebookShare to LinkedInShare to Reddit

Overview

Phase
未知
Intervention
Not specified
Conditions
Not specified
Sponsor
GLAXOSMITHKLINE PERU S.A.,
Enrollment
119
Last Updated
2 years ago
OverviewInvestigatorsEligibility CriteriaOutcomesSimilar Trials

Overview

Brief Summary

No summary available.

Registry
who.int
Start Date
November 23, 2011
End Date
TBD
Last Updated
2 years ago
Study Type
Interventional
Sex
All

Investigators

Sponsor
GLAXOSMITHKLINE PERU S.A.,

Eligibility Criteria

Inclusion Criteria

  • •1\. INFORMED CONSENT: SUBJECTS MUST GIVE THEIR SIGNED AND DATED WRITTEN INFORMED CONSENT TO PARTICIPATE.
  • •2\. TYPE OF SUBJECT: OUTPATIENTS 12 YEARS OF AGE OR OLDER AT THE VISIT 1 (OR ≥ 18 YEARS OF AGE IF LOCAL REGULATIONS OR TE REGULATORY STATUS OF STUDY MEDICATION PERMIT ENROLMENT OF ADULTS ONLY) WITH A DIAGNOSIS OF ASTHMA AS DEFINED BY THE NATIONAL INSTITUTES OF HEALTH \[NIH, 2007], AT LEAST 12 WEEKS PRIOR TO VISIT 1\.
  • •NOTE: TARGET TO RANDOMISE APPROXIMATELY 12 % OF SUBJECTS AGED 12\-17 YEARS.
  • •3\. GENDER: MALE OR ELIGIBLE FEMALE, DEFINED AS NON\-CHILDBEARING POTENTIAL OR CHILDBEARING POTENTIAL USING AN ACCEPTABLE METHOD OF BIRTH CONTROL CONSISTENTLY AND CORRECTLY, AS DEFINED BY THE FOLLOWING:
  • •MALE PARTNER WHO IS STERILE PRIOR TO THE FEMALE SUBJECT´S ENTRY INTO THE STUDY AND IS THE SOLE SEXUAL PARTNER FOR THAT FEMALE SUBJECT.
  • •IMPLANTS OF LEVONORGESTREL.
  • •INJECTABLE PROGESTOGEN.
  • •ORAL CONTRACEPTIVE (EITHER COMBINED ESTROGEN/PROGESTIN OR PROGESTIN ONLY).
  • •ANY INTRAUTERINE DEVICE (IUD) WITH A DOCUMENTED FAILURE RATE OF LESS THAN 1% PER YEAR.

Exclusion Criteria

  • •1\. HISTORY OF LIFE\-THREATENING ASTHMA: DEFINED FOR THIS PROTOCOL AS AN ASTHMA EPISODE THAT REQUIRED INTUBATION AND/OR WAS ASSOCIATED WITH HYPERCAPNEA, RESPIRATORY ARREST OR HYPOXIC SEIZURES WITHIN THE LAST 10 YEARS.
  • •2\. RESPIRATORY INFECTIONS: CULTRE DOCUMENTED OR SUSPECTED BACTERIAL OR VIRAL INFECTION OF THE UPPER OR LOWER RESPIRATORY TRACT, SINUS OR MIDDLE EAR THAT IS NOT RESOLVED WITHIN 4 WEEKS OF VISIT 1 AND LED TO A CHANGE IN ASTHMA MANAGEMENT OR, IN THE OPINION OF THE INVESTIGATOR, IS EXPECTED TO AFFECT THE SUBJECT´S ASTHMA STATUS OR THE SUBJECT´S ABILITY TO PARTICIPATE IN THE STUDY.
  • •3\. ASTHMA EXACERBATION: ANY ASTHMA EXACERBATION WITHIN 12 WEEKS OF VISIT 1 REQUIRING ORAL CORTICOSTEROIDS OR THAT RESULTED IN OVERNIGHT HOSPITALISATION REQUIRING ADDITIONAL TREATMENT FOR ASTHMA WITHIN 6 MONTHS PRIOR TO VISIT 1\.
  • •4\. CONCURRENT RESPIRATORY DISEASE: A SUBJECT MUST NOT HAVE CURRENT EVIDENCE OF PNEUMONIA, PNEUMOTHORAX, ATELECTASIS, PULMONARY FIBROTIC DISEASE, BRONCHOPULMONARY DYSPLASIA, CHRONIC BRONCHITIS, EMPHYSEMA, CHRONIC OBSTRUCTIVE PULMONARY DISEASE, OR OTHER RESPIRATORY ABNORMALITIES OTHER THAN ASTHMA.

Outcomes

Primary Outcomes

Not specified

Similar Trials

Unknown
Not Applicable
A RANDOMIZED, DOUBLE-BLIND, DOUBLE-DUMMY, PLACEBO CONTROLLED, MULTICENTER STUDY OF SUBCUTANEOUS SECUKINUMAB TO DEMONSTRATE EFFICACY AFTER TWELVE WEEKS OF TREATMENT, COMPARED PLACEBO AND ETANERCEPT AND TO ASSESS THE SAFETY, TOLERABILITY AND LONG-TERM EFFICACY UP TO ONE YEAR IN SUBJECTS WITH MODERATE TO SEVERE CHRONIC PLAQUE-TYPE PSORIASIS
PER-054-11OVARTIS BIOSCIENSES PERU S.A.,
Active, not recruiting
Phase 1
A DOUBLE-BLIND, DOUBLE-DUMMY, RANDOMIZED, PLACEBO-CONTROLLED, PARALLEL, DOSE-RANGING STUDY TO EVALUATE THE EFFICACY AND SAFETY OF PF-00547659 IN PATIENTS WITH MODERATE TO SEVERE ULCERATIVE COLITIS (TURANDOT) - TURANDOTCrohn’s Disease (CD) and Ulcerative Colitis (UC)MedDRA version: 14.1Level: LLTClassification code 10045365Term: Ulcerative colitisSystem Organ Class: 10017947 - Gastrointestinal disordersMedDRA version: 14.1Level: PTClassification code 10011401Term: Crohn's diseaseSystem Organ Class: 10017947 - Gastrointestinal disordersTherapeutic area: Diseases [C] - Digestive System Diseases [C06]
EUCTR2012-002030-37-BEPfizer Inc.357
Completed
Not Applicable
A RANDOMIZED, DOUBLE-BLINDED, DOUBLE-DUMMY, PLACEBO-CONTROLLED THOROUGH QTC STUDY WITH SINGLE ORAL DOSES OF CEDAZURIDINE IN HEALTHY SUBJECTSLeukemia10024324
NL-OMON50873Astex Pharmaceuticals, Inc36
Active, not recruiting
Not Applicable
A PHASE II STUDY ASSESSING RANOLAZINE IN ATRIAL FIBRILLATION FOLLWING AN ELECTRICAL CARDIOVERSIOON-PERMANENT ATRIAL FIBRILLATIONMedDRA version: 14.1Level: PTClassification code 10003658Term: Atrial fibrillationSystem Organ Class: 10007541 - Cardiac disordersTherapeutic area: Diseases [C] - Cardiovascular Diseases [C14]
EUCTR2011-002789-18-DEMenarini Ricerche S.p.A240
Active, not recruiting
Phase 1
A PHASE II STUDY ASSESSING RANOLAZINE IN ATRIAL FIBRILLATION FOLLOWING AN ELECTRICAL CARDIOVERSIOON-PERMANENT ATRIAL FIBRILLATIONMedDRA version: 14.0Level: PTClassification code 10003658Term: Atrial fibrillationSystem Organ Class: 10007541 - Cardiac disordersTherapeutic area: Diseases [C] - Cardiovascular Diseases [C14]
EUCTR2011-002789-18-ESMENARINI RICERCHE S.P.A241